The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients and has become a major health problem in developed countries. There is an elemental understanding of the genes and signaling pathways involved in the initiation and progression of this neoplasm. The current hypothesis of the HCC cell origin includes both somatic cells (hepatocytes) and stem cells/progenitor cells. Unlike that in other malignancies such as breast, brain, or hematopoietic cancers, the implication of cancer stem cells in HCC pathogenesis is not yet supported by consistent data. Analysis of somatic genetic alterations and gene expression profiles in HCC samples has provided relevant information on the genes involved in hepatocarcinogenesis, pinpointing a seminal molecular classification of the disease. Nonetheless, a comprehensive genomic analysis of HCC samples using high-resolution platforms in precisely annotated HCCs is clearly needed. Recent data have identified different signaling pathways in liver carcinogenesis (e.g., Wnt-betaCatenin, Hedgehog, tyrosine kinase receptor-related pathways), providing an important potential source of novel molecular targets for new therapies. This review summarizes the most relevant information regarding structural and functional alterations in HCC and describes some of the key signaling pathways implicated in hepatocarcinogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Finishing the euchromatic sequence of the human genome
International Human Genome Sequencing Consortium (2004) · Nature · doi:10.1038/nature03001 · Cited by 4,971
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors
Kallioniemi, A., Kallioniemi, O.-P., Sudar, D., Rutovitz, D., Gray, J. W., Waldman, F., & Pinkel, D. (1992) · Science · doi:10.1126/science.1359641 · Cited by 3,297
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Self-citationCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“%) present with abnormal AFP serum levels, a fact that has been recently correlated with a molecular subclass of aggressive HCCs (S2 class, EpCAM positive) [77–79].”
BackgroundInfluentialForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationWilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Self-citationHoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
“This complexity makes it difficult to identify the causal genetic events promoting HCC development and progression (2, 3).”
BackgroundSelf-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Self-citationCellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Self-citationCoulouarn, C., Factor, V. M., Andersen, J. B., Durkin, M. E., & Thorgeirsson, S. S. (2009) · Oncogene · doi:10.1038/onc.2009.211 · Cited by 733
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
Self-citationLadeiro, Y., Couchy, G., Balabaud, C., Bioulac-Sage, P., Pelletier, L., Rebouissou, S., & Zucman-Rossi, J. (2008) · Hepatology · doi:10.1002/hep.22256 · Cited by 684
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Self-citationGoals and targets for personalized therapy for HCC
Couri, T., & Pillai, A. (2019) · Hepatology International · doi:10.1007/s12072-018-9919-1 · Cited by 530
Choi, J.-Y., Lee, J.-M., & Sirlin, C. B. (2014) · Radiology · doi:10.1148/radiol.14132361 · Cited by 513
The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
Khemlina, G., Ikeda, S., & Kurzrock, R. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0712-x · Cited by 464
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 449
Self-citationAn HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis
Hatziapostolou, M., Polytarchou, C., Aggelidou, E., Drakaki, A., Poultsides, G. A., Jaeger, S. A., Ogata, H., Karin, M., Struhl, K., Hadzopoulou-Cladaras, M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.10.043 · Cited by 445
Fang, Y., Xue, J.-L., Shen, Q., Chen, J., & Tian, L. (2012) · Hepatology · doi:10.1002/hep.25576 · Cited by 425
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Llovet, J. M., & Hernandez-Gea, V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0547 · Cited by 397
Self-citationWnt/β-Catenin Signaling Contributes to Activation of Normal and Tumorigenic Liver Progenitor Cells
Yang, W., Yan, H.-X., Chen, L., Liu, Q., He, Y.-Q., Yu, L.-X., Zhang, S.-H., Huang, D.-D., Tang, L., Kong, X.-N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6691 · Cited by 378
Verslype, C., Rosmorduc, O., & Rougier, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds225 · Cited by 365
Coulouarn, C., Factor, V. M., & Thorgeirsson, S. S. (2008) · Hepatology · doi:10.1002/hep.22283 · Cited by 332
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
Self-citationEpithelial–Mesenchymal Transition in Hepatocellular Carcinoma
van Zijl, F., Zulehner, G., Petz, M., Schneller, D., Kornauth, C., Hau, M., Machat, G., Grubinger, M., Huber, H., & Mikulits, W. (2009) · Future Oncology · doi:10.2217/fon.09.91 · Cited by 305
Histopathology of hepatocellular carcinoma
Schlageter, M., Terracciano, L. M., D’Angelo, S., & Sorrentino, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.15955 · Cited by 294
Chemopreventive strategies in hepatocellular carcinoma
Singh, S., Singh, P. P., Roberts, L. R., & Sanchez, W. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.143 · Cited by 273
Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad
Nejak-Bowen, K. N., & Monga, S. P. S. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.12.010 · Cited by 260
Gender Disparity of Hepatocellular Carcinoma: The Roles of Sex Hormones
Yeh, S.-H., & Chen, P.-J. (2010) · Oncology · doi:10.1159/000315247 · Cited by 256
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Minguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 254
Self-citationCancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies
Liu, Y.-C., Yeh, C.-T., & Lin, K.-H. (2020) · Cells · doi:10.3390/cells9061331 · Cited by 253
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a
Toffanin, S., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., Savic, R., Ward, S. C., Thung, S., Chiang, D. Y., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.009 · Cited by 232
Self-citationReview article: the management of hepatocellular carcinoma
CABRERA, R., & NELSON, D. R. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04200.x · Cited by 222
Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease
Ambade, A., Satishchandran, A., Gyongyosi, B., Lowe, P., & Szabo, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i16.4091 · Cited by 52
Srivastava, S., Thakkar, B., Yeoh, K. G., Ho, K. Y., Teh, M., Soong, R., & Salto-Tellez, M. (2015) · Virchows Archiv · doi:10.1007/s00428-015-1745-4 · Cited by 22
Metadata
- Authors
- Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2007-02
- Volume
- 27
- Issue
- 1
- Pages
- 055-076
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2067691895
- Cited by
- 556
- References
- 186
- FWCI
- 29.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.